Neuroimmune checkpoint molecules, including CD47-SIRPα, PD-1/PD-L1, and other "don't eat me" signals, play crucial roles in regulating immune responses in the brain. Dysregulation of these pathways has emerged as an important mechanism in neurodegenerative diseases, affecting microglial phagocytosis, neuroinflammation, and disease progression. This page explores how checkpoint dysfunction contributes to Alzheimer's disease, Parkinson's disease, and related disorders.
The immune system uses checkpoint molecules to prevent excessive activation and maintain self-tolerance. In the brain, these checkpoints are critical for maintaining proper microglial function and preventing pathological immune responses. Growing evidence suggests that upregulation of checkpoint molecules like CD47 allows pathological proteins to evade clearance, while their modulation may offer therapeutic opportunities for neurodegenerative diseases.
Neuroimmune checkpoints represent a sophisticated regulatory network that balances protective immunity with the risk of autoimmune damage. These molecules are particularly important in the CNS, where resident immune cells (microglia) must carefully distinguish between pathogens, cellular debris, and healthy tissue. In neurodegeneration, this balance is disrupted, leading to either excessive inflammation or impaired clearance of pathological proteins.
flowchart TD
A["Neurons/Astrocytes"] --> B["CD47 Expression"]
A --> C["PD-L1 Expression"]
B --> D["SIRPα Binding"]
C --> E["PD-1 Binding"]
D --> F["Phagocytic Inhibition"]
E --> G["T-cell Exhaustion"]
F --> H["Reduced Amyloid Clearance"]
F --> I["Reduced Tau Clearance"]
F --> J["Reduced Alpha-Syn Clearance"]
H --> K["Protein Accumulation"]
I --> K
J --> K
G --> L["Impaired Immune Surveillance"]
L --> M["Chronic Neuroinflammation"]
M --> N["Neuronal Damage"]
K --> O["Synaptic Loss"]
O --> P["Cognitive Decline"]
N --> P
The CD47-SIRPα axis represents one of the most important "don't eat me" signals in the brain:
CD47 Upregulation:
- Neurons and astrocytes increase CD47 expression in aging and neurodegeneration
- CD47 is overexpressed on amyloid plaques, tau tangles, and Lewy bodies
- This overexpression serves as a molecular shield preventing microglial clearance
SIRPα Signaling:
- Engages Src homology region 2-containing protein tyrosine phosphatase (SHP-1/SHP-2)
- Inhibits actin remodeling necessary for phagocytosis
- Creates a "self" signal that microglia learn to ignore
Role in Protein Clearance:
- Amyloid Evasion: CD47 on amyloid plaques inhibits microglial phagocytosis
- Tau Clearance: CD47 prevents efficient tau protein removal by microglia
- α-Synuclein: CD47 facilitates evasion of α-synuclein pathology clearance
The PD-1/PD-L1 axis has important functions in brain immune regulation:
PD-L1 Expression:
- Expressed on neurons, astrocytes, and microglia
- Decreased in Alzheimer's disease, altering immune regulation
- Provides neuroprotection through immune modulation
T-cell Dysfunction:
- PD-1 signaling induces T-cell exhaustion in neurodegeneration
- Impaired surveillance allows pathological protein spread
- Anti-PD-1 therapy shows promise in preclinical models
Neuroinflammation Modulation:
- PD pathway affects cytokine production
- Regulates microglial activation states
- Influences astrocyte reactivity
SIRPβ1:
- Alternative SIRP family member with complex signaling
- Expressed on microglia and macrophages
- Can either enhance or inhibit phagocytosis depending on context
SIRPγ:
- CD47 receptor on T and B cells
- Involved in lymphocyte regulation in the CNS
Clec10A:
- C-type lectin receptor involved in immune regulation
- Binds to damaged cells and promotes clearance
TREM2 Competition:
- Checkpoint molecules may compete with TREM2 for signaling
- TREM2 variants affect AD risk through phagocytic regulation
The complement system also provides regulatory signals:
CD47-Complement Interplay:
- Complement opsonization (C3b) promotes phagocytosis
- CD47 counterbalances complement-mediated clearance
- This balance is disrupted in neurodegeneration
CD55 and CD59:
- Regulate complement activation on neural cells
- Overexpressed in AD and PD
- Prevent complement-mediated cell lysis
The CD47-SIRPα pathway plays a critical role in AD pathophysiology:
Amyloid Clearance:
- CD47 overexpression on amyloid plaques prevents efficient microglial phagocytosis
- Anti-CD47 antibodies enhance plaque clearance in mouse models
- SIRPα genetic variants affect AD risk
Tau Pathology:
- CD47-SIRPα pathway impedes tau clearance mechanisms
- Tau aggregates are particularly resistant to microglial uptake
- Combined targeting may be necessary
Therapeutic Targeting:
- Anti-CD47 antibodies show promise in AD mouse models
- SIRPα inhibitors are in development
- Combination with complement modulators may enhance efficacy
Checkpoint dysfunction contributes to PD progression:
Alpha-Synuclein:
- CD47 facilitates evasion of α-synuclein pathology clearance
- α-Synuclein oligomers upregulate CD47 expression
- Impaired clearance leads to propagation
Microglial Activation:
- Checkpoint dysregulation alters microglial phenotype
- Chronic activation despite impaired function
- Creates neurotoxic microenvironment
Neuroinflammation:
- Chronic inflammation results from impaired immune regulation
- Elevated CD47 on dopaminergic neurons
- Contributes to progressive degeneration
Checkpoint molecules play complex roles in ALS:
Motor Neuron Protection:
- CD47 may protect motor neurons from excessive phagocytosis
- Protective in early disease stages
- Later becomes detrimental by limiting clearance
Glial Crosstalk:
- Checkpoint molecules modulate astrocyte-microglia communication
- Affects spread of pathology
- Potential therapeutic target
Checkpoint dysfunction in oligodendrocytes:
- CD47 upregulated in oligodendrocytes with GCI
- Impairs clearance of α-synuclein inclusions
- Contributes to white matter pathology
Therapeutic approaches targeting neuroimmune checkpoints:
Anti-CD47 Antibodies:
- Being explored to enhance phagocytosis of pathological proteins
- Magrolimab (5F9) in clinical trials for cancer shows brain penetration
- Preclinical results promising in AD and PD models
SIRPα Inhibitors:
- Small molecules targeting SIRPα signaling
- SIRPαFc fusion proteins as decoy receptors
- Gene therapy approaches under development
PD-1/PD-L1 Modulation:
- Checkpoint inhibitors used in cancer enhance immune surveillance
- May help clear pathological proteins
- Risk of autoimmunity must be considered
Checkpoint blockade with other immunomodulatory approaches:
- With TREM2 modulators: Enhance phagocytosis through multiple pathways
- With complement inhibitors: Overcome "don't eat me" signals
- With anti-inflammatory agents: Balance clearance and inflammation
Important safety considerations exist:
Autoimmunity:
- Systemic checkpoint blockade can cause autoimmune complications
- CNS-specific targeting required to minimize side effects
- Peripheral vs central effects must be distinguished
Off-target Effects:
- Brain-specific targeting required to minimize side effects
- Balance between clearance and tissue damage
- Long-term consequences poorly understood
Balance:
- Complete checkpoint removal may cause excessive inflammation
- Timing of intervention critical
- Patient selection important
| Polymorphism |
Effect |
Disease Association |
| rs12986289 |
Expression |
AD risk |
| rs2276270 |
Phagocytosis |
PD risk |
| rs1050885 |
Protein function |
ALS progression |
| Polymorphism |
Effect |
Disease Association |
| rs3811058 |
SIRPα expression |
AD risk |
| rs2723345 |
Signaling |
PD susceptibility |
| Marker |
AD |
PD |
ALS |
Clinical Utility |
| sCD47 |
Elevated |
Elevated |
Elevated |
Disease progression |
| sPD-1 |
Elevated |
Variable |
Elevated |
Immune activation |
| sPD-L1 |
Decreased |
Variable |
Elevated |
Treatment response |